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| INTRODUC TI ON
In recent years, pediatric-inspired regimens have been adopted by several groups as the treatment strategy for adult patients with acute lymphoblastic leukemia (ALL).
1-3 These regimens consist of long-lasting chemotherapy including induction, consolidation, reinduction, late consolidation, and maintenance phases, usually for up to 2 years. High-dose corticosteroids, asparaginase, and methotrexate are some of the most frequently used agents in these regimens.
Original pediatric-inspired protocols have been modified over the years including addition or removal of drugs, dose intensity, inclusion criteria, measurable residual disease (MRD) assessment, and allocation of patients to a higher intensity treatment or allogeneic hematopoietic stem cell transplantation (HSCT). Whether subsequent modifications of these protocols have led to an improvement in patient outcome is uncertain.
T-cell ALL accounts for up to 20% of all ALL cases and it seems to be slightly more frequent in adults than in children. 4 Until recently, both first line and rescue therapy of ALL did not differ significantly between B-cell precursor (BCP) and T-cell ALL. During the present decade, however, several therapies have been approved or are in advanced phases of investigation for BCP ALL, [5] [6] [7] [8] [9] whereas very few drugs have been approved for T-cell ALL.
10
The aim of the study was to compare the outcome of patients with high-risk T-cell ALL included in two consecutive trials of the Spanish PETHEMA Group (HR-ALL03 and the more contemporary HR-ALL11).
| PATIENTS AND ME THODS

| Patients
All patients diagnosed with T-cell ALL included in the PETHEMA HR- 
Conclusion:
Patients with T-cell ALL included in the HR-11 trial showed better OS than patients in the HR-03, mostly driven by a reduction of NRM.
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| Treatment protocols
Treatment protocols used in the HR-ALL03 (NCT00853008) and HR-ALL11 (NCT01540812) trials were pediatric-inspired regimens.
MRD was assessed by flow cytometry as previously reported. 1 Both trials were approved by a reference institutional research board (IRB) located in Hospital Germans Trias I Pujol (Badalona, Spain) and
IRBs of the participating centers. In both trials, bone marrow (BM)
MRD assessment was performed at the end of induction (weeks [5] [6] and at the end of the third consolidation cycle (weeks [16] [17] [18] protocol allowed the use of native E. coli derived or pegylated asparaginase at the discretion of each center, as it has been recently reported. 12 The comparison of the cumulative doses of the cytotoxic drugs used in the two trials is shown in Table S1 .
HLA typing was recommended in both protocols for all patients and their potential family donors and unrelated donor search was initiated in patients lacking a suitable donor according to the donor selection algorithm in each center. Patients with slow MRD clearance in both trials were allocated to allogeneic HSCT while patients with good MRD clearance received only chemotherapy, including maintenance up to 2 years after achieving CR MRD criteria to undergo allogeneic HSCT in the HR-ALL03 trial included >10% BM blasts on day 14 of induction or BM MRD >0.05% after consolidation-3. In the HR-ALL11 trial, patients were allocated to allogeneic HSCT if they had MRD >0.1% after induction or MRD >0.01% after consolidation-3.
| Definitions
Complete remission was considered when neutrophil counts were >1 × 10 9 /L, platelet count was >100 × 10 9 /L, and there was a normal BM cellularity (>25%) with trilineage hematopoiesis and <5% blast cells and all extramedullary disease had resolved. Resistant disease (RD) was defined as leukemia persistence in patients surviving induction. Early death was considered in patients dying before fulfilling the criteria for CR or RD. Slow cytological response was defined as >10% blasts in BM on day 14. Relapse was defined as disease recurrence at any site after achieving CR ALL treatment-related mortality (TRM) was defined as death in remission in patients receiving treatment for ALL, excluding HSCT. Non-relapse mortality (NRM) included all deaths in remission, including those occurring after HSCT.
Cumulative incidence of relapse (CIR) was calculated from the date of CR to the date of relapse. Overall survival (OS) was measured from the time of entry in the protocol to the time of death by any cause or last follow-up. Event-free survival (EFS) was defined from the time of entry in the protocol to the date of induction treatment failure, or relapse, or death from any cause, whichever occurred first.
| Endpoints and statistical analysis
The primary endpoints of the study were OS and EFS. Secondary endpoints included CR rate, CIR, and treatment toxicity. A descriptive analysis of the main demographic, clinical, and laboratory variables for the whole series and by protocol was performed.
Characteristics between two groups were compared with the chisquare test or Fisher's exact test (for categorical variables) and the
Mann-Whitney U test or the median test (for continuous variables).
EFS and OS were plotted with the Kaplan-Meier method and were compared with the log-rank test. 13 CIR and NRM were estimated by the cumulative incidence method considering them as competing events and comparisons were performed by Gray's test. 14 A secondary analysis was performed with the transplant patients censored at the time of HSCT. The analysis of chemotherapy vs HSCT was performed including all patients who achieved CR1 and completed early consolidation. Both groups were compared by the landmark method using a fixed time (5 months after beginning of induction) after the end of early consolidation as the landmark time.
Multivariate analysis for OS was performed with the Cox proportional hazards regression model. 15 Ninety-five per cent confidence intervals (95% CIs) were calculated for the probabilities. The significance level was fixed at P < 0.05. All statistical analyses were performed using SPSS (version 24) and R software (version 3.3.2).
| RE SULTS
| Patients characteristics
One hundred and sixty-nine patients with T-cell ALL were enrolled in both trials (104 in the HR-ALL03 and 65 in the HR-ALL11).
Patient-related and disease-related characteristics were similar between both groups (Table 1) 
| Slow responders to induction and CR rate
Of the 169 patients starting induction therapy, 162 were assessed for early response on day +14 (100 in the HR-ALL03 and 62 in the HR-ALL11). Eighty (51%) patients were considered to have slow cytological response on day +14 of induction therapy (49% in the HR-ALL 03% and 53% in the HR-ALL11, P = 0.600). Of 164 evaluable patients, in the HR-11 trials achieved CR with low MRD (<0.1%), (P = 0.569).
| Event-free survival and overall survival
Probability of EFS at 2 years for all patients was 41% (95% CI 33-49).
EFS for patients in the HR-ALL03 trial was 38% (95% CI 29-47) while for patients in the HR-ALL11 trial was 46% (95% CI 32-60), P = 0.186.
Probability of OS at 2 years for all patients was 50% (95% CI 42-58):
44% (95% CI 34-54) in the HR-ALL03 trial and 65% (95% CI 51-79) in the HR-ALL11 trial, P = 0.026 ( Figure 1A ,B).
The univariate and multivariate analyses of prognostic factors associated with lower OS are summarized in 
| Relapse
| Non-relapse mortality and treatmentrelated deaths
The 2-year cumulative incidence of NRM for all patients included in the study was 13% (95% CI 8-19): 17% (95% CI 10-25) in the HR-ALL03 trial and 6% (95% CI 1-14) in the HR-ALL11 protocol (P = 0.074; Figure 1D ).
Regarding TRM, the 2 years cumulative incidence for the whole cohort censored at the time of transplantation was 7% (95% CI 3-12).
TRM for patients in the HR-ALL03 trial was 8% (95% CI 4-16) while for patients in the HR-ALL11 trail was 3% (95% CI 1-11), P = 0.324.
Nine patients died of treatment-related causes during induction (Table 3 ).
| Postremission therapy: allogeneic stem cell transplantation vs chemotherapy
Of 
| D ISCUSS I ON
The outcome of adult patients with T-cell ALL has been reported to be slightly worse than for BCP ALL in some 16, 17 but not all studies evaluating multicenter protocols. 1, 18 However, clinical studies focusing exclusively on T-cell ALL patients are scarce. 19, 20 Moreover, the outcome of T-cell ALL patients treated with pediatric-inspired regimens has not been investigated in depth. 21 The study reported herein is one of the largest reports exclusively focusing on adult 
TA
TA B L E 3 Frequency of treatment-related deaths according to treatment phase
Toxic deaths (phases of treatment) HR-03 HR-11 P value Induction, n (%) 7/104 (7) 2/65 (3) 0.255
No treatment-related deaths were seen during maintenance phases.
F I G U R E 2 OS (A), CIR (B)
, and non-relapse mortality (C) in patients allocate to allogeneic HSCT or chemotherapy only in CR1. CIR, cumulative incidence of relapse; OS, overall survival [Colour figure can be viewed at wileyonlinelibrary.com]
T-cell ALL and the only one comparing two different pediatric-inspired regimens in adults.
In this study, we observed an improvement in OS with the more contemporary HR-ALL11 protocol compared with the older HR-ALL03 protocol. However, such survival benefit seemed more dependent on our capacity of lowering toxicity and managing relapsed patients rather than in improving efficacy. Irrespective of the protocol in which they were included, patients with T-cell ALL treated with pediatric-inspired regimens with good MRD clearance showed promising long-term survival without allogeneic HSCT in CR1.
We observed similar rates of slow responders on day +14 of induction, CR rate after induction and long-term EFS between both protocols, suggesting that the several modifications introduced in the more contemporary protocol including lower dose of several drugs in induction and consolidation (except for higher dose of MTX), a wider definition of high-risk patients and a centralized review of MRD by flow cytometry did not result in higher anti-leukemic efficacy. Of note, this attenuation of the treatment intensity did also not result in an impaired efficacy of the protocol and might have had potential benefits in terms of both short-term (see below) and long-term morbidity and mortality.
Regarding toxicity, we observed a trend toward lower TRM in the more contemporary protocol. Because of the low number of events, this difference was not statistically significant although we consider that a 64% reduction of NRM (17% vs 6%) is clinically meaningful.
Reasons behind this trend include the lower burden of chemotherapy intensity (both with dose reduction and removal of some chemotherapy agents) especially in the consolidation phases that led to a reduction of the risk of death in consolidation in the HR-ALL11
protocol (6% vs 0%). Noteworthy, the increase in the dose of methotrexate (from 3 g/m 2 to 5 g/m 2 ) in four of the six consolidation cycles was tolerable in this cohort of T-ALL patients.
Survival after relapse was higher (although not statistically significant) in the HR-ALL11 trial vs HR-ALL03 protocol although this was not due to a higher allogeneic HSCT indication in CR2. Also, it is unlikely that this benefit could be explained by the use of novel therapies in recent years, since only nelarabine was approved for relapse/ refractory T-cell ALL in Europe during the study period. Noteworthy, a homogeneous protocol for relapsed patients was implemented in the PETHEMA centers in 2012, which might have had an influence in optimizing rescue therapy for patients with relapsed ALL.
The higher OS observed in the HR-ALL11 protocol compared with the HR-ALL03 cannot be attributed to a specific cause. 
